Skip to main content

Table 9 Comparison of HFE gene status with iron status.

From: The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients

  Hepatic Iron Staining Serum Iron (ug/dL) Ferritin (ng/mL) Iron binding capacity (ug/dL) Transferrin saturation (%)
  N with data Iron staining (%) N with data Median [Q1, Q3] Abnormal (% > 160) N with data Median [Q1, Q3] Abnormal (% > 400) N with data Median [Q1, Q3] Abnormal (% > 428) N with data Median [Q1, Q3] Abnormal (% > 55)
C282Y               
   Normal/Hetero (N = 1061) 1061 182 (17%) 892 62 [50, 79] 5 (<1%) 898 99 [50, 167] 34 (4%) 893 316 [287, 349] 24 (3%) 889 20 [15, 25] 3 (<1%)
   Homo (N = 3) 3 1 (33%) 2 106 [106, 106] 0 (0%) 2 306 [112, 500] 1 (50%) 2 316 [284, 349] 0 (0%) 2 34 [30, 37] 0 (0%)
p-value A   0.43   NA 0.99   NA 0.076   NA 0.99   NA 0.99
H63D               
   Normal/Hetero (N = 1034) 1034 178 (17%) 868 62 [49, 79] 5 (<1%) 872 99 [50, 167] 33 (4%) 869 316 [287, 349] 23 (3%) 865 20 [15, 25] 2 (<1%)
   Homo (N = 30) 30 5 (17%) 26 63 [57, 67] 0 (0%) 28 86 [44, 171] 2 (7%) 26 316 [272, 348] 1 (4%) 26 21 [17, 24] 1 (33%)
p-value A   0.99   0.75 0.99   0.75 0.30   0.38 0.51   0.49 0.085
C282Y/H63D*               
   Allele dose <2 (N = 1011) 1011 172 (17%) 847 61 [49, 78] 3 (<1%) 851 99 [50, 167] 30 (4%) 848 317 [288, 349] 23 (3%) 844 19 [15, 25] 0 (0%)
   Allele dose 2 + (N = 53) 53 11 (21%) 47 69 [59, 90] 2 (4%) 49 91 [49, 187] 5 (10%) 47 298 [272, 335] 1 (2%) 47 24 [19, 32] 3 (6%)
p-value A   0.46   0.0005 0.024   0.98 0.037   0.0073 0.99   <.0001 0.0001
  1. *An allele dose of 2+ includes all patients that were Homozygous for C282Y, Homozygous for H63D, or Heterozygous for both C282Y and H63D.
  2. A = p-values are resulted from Fisher's exact test and wilcoxon rank sum test